Smith & Nephew SNATS - ADR Peer Comparison
$29.13
$-0.17
(-0.58%)
As on 27-Aug-2026 16:00EDT
Market cap
$12,153 Mln
Revenue (TTM)
$8,463 Mln
P/E Ratio
19.9
P/B Ratio
2.4
Div. Yield
2.7 %
Edit
| Smith & Nephew SNATS - ADR | Penumbra (PEN) | Glaukos Corp (GKOS) | Bio-Rad Laboratories | Repligen (RGEN) | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
12,153 | 12,753 | 10,906 | 9,762 | 10,222 |
Revenue ($ Mln) |
6,164 | 1,505 | 613 | 2,589 | 785 |
Net Profit ($ Mln) |
625.00 | 160.59 | -188.05 | 222.40 | 41.54 |
Net Margin (%) |
5.41 | 10.67 | -30.68 | 8.59 | 5.29 |
RoE (%) |
11.84 | 10.86 | -28.10 | 3.04 | 1.97 |
Price to Earnings |
19.89 | 79.35 | -- | 44.47 | 251.57 |
Price-To-Book |
2.37 | 8.41 | 16.38 | 1.26 | 4.84 |
Income Statement ($ Mln)
| Smith & Nephew SNATS - ADR | Penumbra (PEN) | Glaukos Corp (GKOS) | Bio-Rad Laboratories | Repligen (RGEN) | |
|---|---|---|---|---|---|
|
Operating Revenue
|
6,164.00 | 1,403.67 | 507.44 | 2,583.20 | 738.26 |
|
Cost of Revenue
|
1,957.00 | 461.23 | 114.23 | 1,239.60 | 390.63 |
|
Gross Profit
|
4,207.00 | 942.44 | 393.22 | 1,343.60 | 347.62 |
|
Operating Expenses
|
3,413.00 | 753.19 | 479.95 | 1,077.50 | 288.05 |
|
Operating Profit (EBIT)
|
794.00 | 189.25 | -86.73 | 270.50 | 59.58 |
|
Other Income
|
-- | -- | -- | -- | -- |
|
Profit before Tax
|
779.00 | 205.13 | -193.04 | 995.50 | 62.38 |
|
Provision for Tax
|
154.00 | 27.44 | -5.35 | 235.60 | 13.49 |
|
Profit after Tax (Net Income)
|
625.00 | 177.69 | -187.69 | 759.90 | 48.89 |
|
Minority Interest
|
-- | -- | -- | -- | -- |
|
Consolidated Profit
|
625.00 | 177.69 | -- | -- | -- |
Liabilities ($ Mln)
| Smith & Nephew SNATS - ADR | Penumbra (PEN) | Glaukos Corp (GKOS) | Bio-Rad Laboratories | Repligen (RGEN) | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
5,289.00 | 1,427.60 | 656.16 | 7,453.60 | 2,106.13 |
|
Minority Interest
|
-- | -- | -- | -- | -- |
|
Non-Current Liabilities
|
3,573.00 | 215.78 | 136.06 | 2,605.90 | 707.74 |
|
Current Liabilities
|
1,595.00 | 183.13 | 101.28 | 517.00 | 135.83 |
|
Total Liabilities
|
10,457.00 | 1,826.52 | 893.49 | 10,576.50 | 2,949.70 |
Assets ($ Mln)
| Smith & Nephew SNATS - ADR | Penumbra (PEN) | Glaukos Corp (GKOS) | Bio-Rad Laboratories | Repligen (RGEN) | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
6,354.00 | 609.84 | 418.50 | 7,670.30 | 1,812.31 |
|
Current Assets
|
4,103.00 | 1,216.68 | 474.98 | 2,906.20 | 1,137.39 |
|
Total Assets
|
10,457.00 | 1,826.52 | 893.49 | 10,576.50 | 2,949.70 |
|
Total Debt*
|
3,327.00 | 219.70 | 139.64 | 1,531.00 | 689.95 |
|
Net Current Assets
|
2,508.00 | 1,033.55 | 373.71 | 2,389.20 | 1,001.56 |
Cashflow ($ Mln)
| Smith & Nephew SNATS - ADR | Penumbra (PEN) | Glaukos Corp (GKOS) | Bio-Rad Laboratories | Repligen (RGEN) | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
1,285.00 | 238.66 | -46.34 | 532.20 | 117.42 |
|
Cash Flow from Investing Activities
|
-406.00 | -404.59 | -77.61 | -189.70 | -298.47 |
|
Cash from Financing Activities
|
-955.00 | 26.53 | 11.89 | -283.20 | -15.21 |
|
Net Cash Inflow / Outflow
|
-- | -- | -- | -- | -- |
Ratios
Profitability Ratios
| Smith & Nephew SNATS - ADR | Penumbra (PEN) | Glaukos Corp (GKOS) | Bio-Rad Laboratories | Repligen (RGEN) | |
|---|---|---|---|---|---|
|
ROCE (%)
|
7.27 | 11.76 | -22.53 | 8.98 | 1.79 |
|
ROE (%)
|
11.84 | 13.78 | -26.38 | 10.84 | 2.40 |
|
ROA (%)
|
6.01 | 10.58 | -20.09 | 7.62 | 1.69 |
|
EBIT Margin (%)
|
-- | -- | -- | -- | -- |
|
Net Margin (%)
|
10.14 | 12.66 | -36.99 | 29.42 | 6.62 |
|
Cash Profit Margin (%)
|
-- | -- | -- | -- | -- |
Growth Ratios
| Smith & Nephew SNATS - ADR | Penumbra (PEN) | Glaukos Corp (GKOS) | Bio-Rad Laboratories | Repligen (RGEN) | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
0.06 | 0.17 | 0.32 | 0.01 | 0.16 |
|
EBIT Growth (%)
|
-- | -- | -- | -- | -- |
|
Net Profit Growth (%)
|
51.70 | 1,168.11 | -28.23 | 141.20 | 291.64 |
|
EPS Growth (%)
|
0.53 | 11.64 | -0.24 | 1.43 | 2.90 |
|
Book Value Growth (%)
|
-- | -- | -- | -- | -- |
Valuation Ratios
| Smith & Nephew SNATS - ADR | Penumbra (PEN) | Glaukos Corp (GKOS) | Bio-Rad Laboratories | Repligen (RGEN) | |
|---|---|---|---|---|---|
|
Price / Earnings
|
22.91 | 68.93 | -34.59 | -- | 189.42 |
|
Price / Book Value
|
2.71 | 8.58 | 9.90 | -- | 4.40 |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
12.79 | 53.25 | -43.50 | -- | 55.90 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| Smith & Nephew SNATS - ADR | Penumbra (PEN) | Glaukos Corp (GKOS) | Bio-Rad Laboratories | Repligen (RGEN) | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.63 | 0.15 | 0.21 | 0.21 | 0.33 |
|
Short term debt to equity ratio
|
0.03 | 0.01 | -- | 0.01 | 0.01 |
|
Current Ratio
|
2.57 | 6.64 | 4.69 | 5.62 | 8.37 |
|
Quick Ratio
|
1.25 | 4.29 | 4.06 | 4.19 | 7.12 |
|
Interest Coverage
|
6.21 | 157.46 | -40.65 | 21.32 | 3.69 |
Operating Efficiency Ratios
| Smith & Nephew SNATS - ADR | Penumbra (PEN) | Glaukos Corp (GKOS) | Bio-Rad Laboratories | Repligen (RGEN) | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
23.18 | 13.54 | 21.40 | 18.29 | 21.48 |
|
Asset Turnover
|
0.59 | 0.84 | 0.54 | 0.26 | 0.26 |
|
Receivable days
|
78.10 | 46.54 | 60.95 | 65.39 | 72.41 |
|
Inventory Days
|
420.31 | 331.92 | 193.84 | 221.09 | 146.53 |
|
Payable days
|
209.22 | 26.16 | 60.19 | 37.02 | 29.05 |
|
Cash Conversion Cycle
|
289.19 | 352.30 | 194.60 | 249.46 | 189.88 |
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
